Financial Performance - Insmed reported a quarterly loss of $1.54 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.07, and compared to a loss of $1.32 per share a year ago [1] - The earnings surprise for this quarter was -43.78%, and the company has not surpassed consensus EPS estimates in the last four quarters [2] - Revenues for the quarter were $263.84 million, slightly missing the Zacks Consensus Estimate by 0.01%, but showing significant growth from $104.44 million year-over-year [3] Stock Performance - Insmed shares have declined approximately 13.2% since the beginning of the year, while the S&P 500 has gained 0.5% [4] - The current Zacks Rank for Insmed is 2 (Buy), indicating expectations for the stock to outperform the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.77 on revenues of $297.17 million, and for the current fiscal year, it is -$2.68 on revenues of $1.45 billion [8] - The Medical - Biomedical and Genetics industry, to which Insmed belongs, is currently in the top 36% of Zacks industries, suggesting a favorable outlook for stocks in this sector [9]